From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Accelerating Immune Response to Biodefense Vaccines

by Global Biodefense Staff
June 13, 2012

The deadline is fast approaching for companies to submit proposals towards advanced development of medical countermeasures for use in settings following the intentional release or naturally occurring outbreak of high priority pathogens.

The National Institute of Allergy and Infectious Diseases (NIAID) funding effort seeks to develop candidate products containing both a vaccine component and a technology that accelerates the immune response.

The Broad Agency Announcement (BAA) recognizes that use of vaccines in response to a significant bioterrorism or public health threat would be greatly enhanced by developing vaccines that are easy to deliver, produce protective immunity with one dose of vaccine and do not require a cold chain for storage or distribution.

Eligible vaccine candidate products include those for agents identified as NIAID Category A and B Priority Pathogens such as plague, smallpox, Q fever and tularemia, excluding B. anthracis. The technology components used in the proposed candidate product may, for example, consist of a new adjuvant, an immune modulator, a formulation technology or a delivery platform designed to enhance the protective immune response.

Per the BAA, simply changing a vaccine formulation, such as taking a liquid to a stable lyophilized vaccine formulation, would not be sufficient to meet the objectives.

The eventual goal is to enable the U.S. Government to stockpile these medical countermeasures and associated technologies to protect the American public following a biological event. Product developers should be cognizant of the logistical implications of using these products during a public health emergency.

NIAID estimates that one or more contracts may be issued for a total cost of up $44.5 million for a five-year period of performance. Full details are available under Solicitation Number: BAA-NIAID-DMID-NIHAI2010103. The final response deadline is June 23, 2012.

From Our Partners
Tags: AnthraxBAABioterrorismSmallpoxVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC